219671-91-7

Basic information

• Product Name: Benzonitrile, 3-bromo-4-[(2-methoxyethoxy)methoxy]-
• CAS NO: 219671-91-7
• Molecular Formula: C11H12BrNO3
• Molecular Weight: 286.125
• Mol File: 219671-91-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzonitrile, 3-bromo-4-[(2-methoxyethoxy)methoxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 3-bromo-4-[(2-methoxyethoxy)methoxy]-(219671-91-7)
• EPA Substance Registry System: Benzonitrile, 3-bromo-4-[(2-methoxyethoxy)methoxy]-(219671-91-7)

Safety Data

• Hazardous Substances Data: 219671-91-7(Hazardous Substances Data)

Upstream product

• 3970-21-6 2-Methoxyethoxymethyl chloride 
• 2315-86-8 3-bromo-4-hydroxybenzonitrile 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 

Downstream Products

• 731015-99-9 C₁₁H₁₄BrNO₄ 
• 583031-84-9 4-(2-methoxy-ethoxymethoxy)-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzonitrile 

Relevant articles and documents

HETEROARYL DERIVATIVES AND USES THEREOF

The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.